Bristol-Myers Squibb Company (BMY)

Basic

  • Market Cap

    $102.91B

  • EV

    $131.84B

  • Shares Out

    2,022.19M

  • Revenue

    $45.01B

  • Employees

    34,100

Margins

  • Gross

    76.63%

  • EBITDA

    40.93%

  • Operating

    19.22%

  • Pre-Tax

    18.75%

  • Net

    17.83%

  • FCF

    28.11%

Returns (5Yr Avg)

  • ROA

    4.53%

  • ROTA

    19.72%

  • ROE

    10.92%

  • ROCE

    9.04%

  • ROIC

    8.02%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $56.7

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $12.28B

  • Net Debt

    $28.88B

  • Debt/Equity

    1.41

  • EBIT/Interest

    7.45

Growth (CAGR)

  • Rev 3Yr

    1.91%

  • Rev 5Yr

    14.81%

  • Rev 10Yr

    10.63%

  • Dil EPS 3Yr

    -1.12%

  • Dil EPS 5Yr

    5.1%

  • Dil EPS 10Yr

    9.62%

  • Rev Fwd 2Yr

    1.6%

  • EBITDA Fwd 2Yr

    2.63%

  • EPS Fwd 2Yr

    -2.01%

  • EPS LT Growth Est

    -1.21%

Dividends

  • Yield

  • Payout

    59.56%

  • DPS

    $2.31

  • DPS Growth 3Yr

    7.88%

  • DPS Growth 5Yr

    7.49%

  • DPS Growth 10Yr

    5.06%

  • DPS Growth Fwd 2Yr

    4.46%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Total Revenues

26,145

42,518

46,385

46,159

45,006

Total Revenues % Chg.

15.9%

62.6%

9.1%

-0.5%

-2.5%

Cost of Goods Sold, Total

7,898

11,773

9,940

9,781

10,518

Gross Profit

18,247

30,745

36,445

36,378

34,488

Selling General & Admin Expenses, Total

4,969

7,618

7,655

7,703

7,678

R&D Expenses

6,066

10,048

10,195

9,201

9,112

Amortization of Goodwill and Intangible Assets

1,135

9,688

10,023

9,595

9,047

Other Operating Expenses, Total

12,170

27,354

27,873

26,499

25,837

Operating Income

6,077

3,391

8,572

9,879

8,651

Interest Expense, Total

-898

-1,381

-1,303

-1,205

-1,161

Interest And Investment Income

464

121

39

171

449

Net Interest Expenses

-434

-1,260

-1,264

-1,034

-712

Income (Loss) On Equity Invest.

-5

72

231

-108

-38

Currency Exchange Gains (Loss)

-13

23

32

148

160

Other Non Operating Income (Expenses)

1,496

1,528

1,708

1,818

2,079

EBT, Excl. Unusual Items

7,121

3,754

9,279

10,703

10,140

Restructuring Charges

-564

-538

-160

-144

-535

Merger & Related Restructuring Charges

-1,072

-717

-564

-863

-326

Gain (Loss) On Sale Of Investments

357

1,157

514

-693

-122

Gain (Loss) On Sale Of Assets

1,168

55

9

211

Asset Writedown

-15

-98

-107

In Process R&D Expenses

-12,533

-1,159

-815

-913

Legal Settlements

-77

194

-82

-178

-10

Other Unusual Items

-1,943

1,757

261

-410

313

EBT, Incl. Unusual Items

4,975

-6,871

8,098

7,713

8,440

Income Tax Expense

1,515

2,124

1,084

1,368

400

Earnings From Continuing Operations

3,460

-8,995

7,014

6,345

8,040

Minority Interest

-21

-20

-20

-18

-15

Net Income

3,439

-9,015

6,994

6,327

8,025

Net Income to Common Incl Extra Items

3,439

-9,015

6,994

6,327

8,025

Net Income to Common Excl. Extra Items

3,439

-9,015

6,994

6,327

8,025

Total Shares Outstanding

2,251

2,244

2,176

2,098

2,021

Weighted Avg. Shares Outstanding

1,705

2,258

2,221

2,130

2,069

Weighted Avg. Shares Outstanding Dil

1,712

2,258

2,245

2,146

2,078

EPS

2

-4

3.1

3

3.9

EPS Diluted

2

-4

3.1

3

3.9

EBITDA

7,798

13,824

19,329

20,161

18,420